$1,318.00
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Ablation or embolization
10 Radiation therapy
10 Chemotherapy
10 Targeted therapy
11 Immunotherapy
11 Drugs used specifically for the treatment of PNETs
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
33 RECENT EVENTS AND ANALYST OPINION
33 Anktiva for Pancreatic Cancer (January 18, 2022)
34 CPI-613 for Pancreatic Cancer (October 28, 2021)
36 ERY-ASP for Pancreatic Cancer (October 25, 2021)
38 Relacorilant for Pancreatic Cancer (June 22, 2021)
39 GV1001 for Pancreatic Cancer (June 6, 2021)
40 Motixafortide for Pancreatic Cancer (December 16, 2020)
42 Masitinib for Pancreatic Cancer (December 4, 2020)
45 KEY UPCOMING EVENTS
46 PROBABILITY OF SUCCESS
47 LICENSING AND ASSET ACQUISITION DEALS
47 Synthetic Biologics To Acquire Immunotherapy Firm VCN
47 Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
47 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
48 Chinese Cell Developers To Jointly Develop Solid Tumor Therapies
48 Processa Licenses Global Rights For RX-3117 From Ocuphire
48 Laevoroc Oncology Acquires Worldwide Patents For LR06
48 Lantern Pharma Enters Research And Development Collaboration with Actuate Therapeutics
48 CytoImmune Acquires City Of Hope Cell Therapy IP
49 University of Texas MD Anderson Cancer Center Unveils Collaboration With TriSalus Life Sciences
49 MD Anderson Inks New Cancer Collaboration With Mirati, Orionis
49 Qilu Obtains Greater China Rights To Cend’s Cancer Candidate
51 REVENUE OPPORTUNITY
54 CLINICAL TRIAL LANDSCAPE
55 Sponsors by status
56 Sponsors by phase
57 Recent events
61 BIBLIOGRAPHY
62 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
18 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
18 Figure 3: Pipeline drugs for pancreatic cancer, by company
19 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
19 Figure 5: Pipeline drugs for pancreatic cancer, by classification
34 Figure 6: Anktiva for Pancreatic Cancer (January 18, 2022): Phase II – QUILT-88
36 Figure 7: CPI-613 for Pancreatic Cancer (October 28, 2021): Phase III – AVENGER 500 (w/mFolfirinox)
39 Figure 8: Relacorilant for Pancreatic Cancer (June 22, 2021): Phase III – RELIANT (w/Nab-Paclitaxel)
42 Figure 9: Motixafortide for Pancreatic Cancer (December 16, 2020): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
44 Figure 10: Masitinib for Pancreatic Cancer (December 4, 2020): Phase III – AB12005
55 Figure 11: Key upcoming events in pancreatic cancer
46 Figure 12: Probability of success in the pancreatic cancer pipeline
54 Figure 13: Clinical trials in pancreatic cancer
54 Figure 14: Top 10 drugs for clinical trials in pancreatic cancer
55 Figure 15: Top 10 companies for clinical trials in pancreatic cancer
55 Figure 16: Trial locations in pancreatic cancer
56 Figure 17: Pancreatic cancer trials status
57 Figure 18: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of pancreatic cancer, 2019–28
16 Table 2: Marketed drugs for pancreatic cancer
20 Table 3: Pipeline drugs for pancreatic cancer in the US
33 Table 4: Anktiva for Pancreatic Cancer (January 18, 2022)
35 Table 5: CPI-613 for Pancreatic Cancer (October 28, 2021)
37 Table 6: ERY-ASP for Pancreatic Cancer (October 25, 2021)
38 Table 7: Relacorilant for Pancreatic Cancer (June 22, 2021)
40 Table 8: GV1001 for Pancreatic Cancer (June 6, 2021)
41 Table 9: Motixafortide for Pancreatic Cancer (December 16, 2020)
43 Table 10: Masitinib for Pancreatic Cancer (December 4, 2020)
52 Table 11: Historical global sales, by drug ($m), 2016–20
53 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!